HeadInvest LLC’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.96M Buy
1,634
+74
+5% +$75.6K 0.37% 69
2026
Q1
$1.43M Buy
1,560
+73
+5% +$74K 0.29% 79
2025
Q4
$1.6M Sell
1,487
-67
-4% -$64.1K 0.32% 71
2025
Q3
$1.19M Buy
1,554
+50
+3% +$37.2K 0.25% 82
2025
Q2
$1.17M Buy
1,504
+349
+30% +$271K 0.25% 77
2025
Q1
$954K Buy
1,155
+365
+46% +$304K 0.19% 102
2024
Q4
$610K Buy
790
+92
+13% +$76.2K 0.12% 133
2024
Q3
$618K Sell
698
-5
-0.7% -$4.5K 0.11% 134
2024
Q2
$636K Buy
703
+29
+4% +$23.2K 0.13% 122
2024
Q1
$524K Sell
674
-18
-3% -$12.8K 0.1% 141
2023
Q4
$403K Sell
692
-25
-3% -$14.6K 0.08% 164
2023
Q3
$386K Sell
717
-10
-1% -$5.15K 0.08% 159
2023
Q2
$384K Sell
727
-146
-17% -$61.2K 0.08% 162
2023
Q1
$300K Buy
873
+15
+2% +$5.06K 0.07% 181
2022
Q4
$314K Sell
858
-50
-6% -$17.7K 0.07% 176
2022
Q3
$294K Sell
908
-100
-10% -$31.7K 0.07% 174
2022
Q2
$327K Sell
1,008
-30
-3% -$9.01K 0.07% 169
2022
Q1
$297K Hold
1,038
0.06% 189
2021
Q4
$287K Sell
1,038
-35
-3% -$8.87K 0.05% 200
2021
Q3
$248K Sell
1,073
-70
-6% -$17.3K 0.05% 199
2021
Q2
$262K Buy
+1,143
New +$230K 0.05% 199

Other funds holding LLY

HeadInvest LLC's LLY Position: Q2 2026 in Review

HeadInvest LLC increased its Eli Lilly (LLY) stake by 4.7% in Q2 2026, buying an estimated $75.6K and bringing the position to 1,634 shares worth $1.96M. The position accounts for 0.37% of the portfolio, ranked #69.

HeadInvest LLC first reported a position in LLY in Q2 2021 and has held it in 21 quarters since. 4,618 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • HeadInvest LLC held 1,634 shares of Eli Lilly worth $1.96M as of Q2 2026.
  • HeadInvest LLC bought 74 Eli Lilly shares in Q2 2026, an estimated $75.6K.
  • Eli Lilly made up 0.37% of HeadInvest LLC's portfolio in Q2 2026, its #69 holding.
  • HeadInvest LLC first reported a position in Eli Lilly in Q2 2021 and has held it in 21 quarters since.
  • 4,618 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on HeadInvest LLC's 13F filing for Q2 2026, filed 14 Aug 2026.